Walvax Biotechnology Co. Ltd. | Ownership
Companies that own Walvax Biotechnology Co. Ltd.
Truvalue Asset Management Co. Ltd.
70,200,000
5.67%
0
15.92%
12/12/2017
Huashang Fund Management Co., Ltd.
28,769,570
2.33%
-15,054,124
3.81%
09/30/2017
First Seafront Fund Management Co., Ltd.
25,943,600
2.1%
25,943,600
2.25%
10/16/2017
Bohai Huijin Securities Asset Management Co. Ltd.
12,971,802
1.05%
12,971,802
28.26%
10/16/2017
E Fund Management Co., Ltd.
8,573,651
0.69%
2,701,147
0.19%
12/31/2017
Fullgoal Fund Management Co., Ltd.
5,645,825
0.46%
-161,773
0.18%
12/31/2017
ABC-CA Fund Management Co., Ltd.
4,369,798
0.35%
4,369,798
0.89%
12/31/2017
Guotai Asset Management Co., Ltd.
2,663,240
0.22%
2,663,240
0.13%
12/31/2017
Huatai-PineBridge Fund Management Co., Ltd.
2,440,276
0.2%
2,440,276
0.16%
12/31/2017
Chang Xin Asset Management Co., Ltd.
1,999,951
0.16%
1,999,951
0.26%
12/31/2017
| Address |
19/F, Building 9A, Dingyi Tiancheng
Kunming Yunnan 650106
China
|
|
Employees
|
- |
| Website |
http://www.walvax.com |
| Updated |
07/08/2019 |
| Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. Its products include haemophilus influenzae type b conjugate vaccine in vials and pre-encapsulation type; lyophilized type A and C, and ACYW135 meningococcal polysaccharide conjugate vaccine. The company was founded on January 16, 2001 and is headquartered in Kunming, China. |
